News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
274,232 Results
Type
Article (14389)
Company Profile (105)
Press Release (259730)
Multimedia
Podcasts (74)
Webinars (13)
Section
Business (88382)
Career Advice (477)
Deals (15413)
Drug Delivery (73)
Drug Development (36788)
Employer Resources (55)
FDA (6395)
Job Trends (6248)
News (150876)
Policy (14143)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (446)
Accelerated approval (13)
Adcomms (8)
Allergies (69)
Alliances (23333)
ALS (56)
Alzheimer's disease (478)
Antibody-drug conjugate (ADC) (99)
Approvals (6584)
Artificial intelligence (203)
Autoimmune disease (45)
Automation (13)
Bankruptcy (150)
Best Places to Work (4378)
BIOSECURE Act (10)
Biosimilars (119)
Biotechnology (40)
Bladder cancer (38)
Brain cancer (30)
Breast cancer (172)
Cancer (1323)
Cardiovascular disease (155)
Career advice (426)
Career pathing (13)
CAR-T (50)
CDC (6)
Cell therapy (158)
Cervical cancer (9)
Clinical research (32064)
Collaboration (738)
Compensation (327)
Complete response letters (34)
COVID-19 (780)
CRISPR (46)
C-suite (443)
Cystic fibrosis (62)
Data (1832)
Denatured (18)
Depression (45)
Diabetes (126)
Diagnostics (1385)
Digital health (9)
Diversity (2)
Diversity, equity & inclusion (15)
Drug discovery (119)
Drug pricing (116)
Drug shortages (12)
Duchenne muscular dystrophy (84)
Earnings (33528)
Editorial (20)
Employer branding (8)
Employer resources (50)
Events (39011)
Executive appointments (534)
FDA (7504)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (442)
Gene editing (77)
Generative AI (18)
Gene therapy (177)
GLP-1 (447)
Government (1412)
Grass and pollen (4)
Guidances (167)
Healthcare (3589)
HIV (12)
Huntington's disease (9)
IgA nephropathy (37)
Immunology and inflammation (74)
Immuno-oncology (15)
Indications (53)
Infectious disease (845)
Inflammatory bowel disease (73)
Inflation Reduction Act (7)
Influenza (25)
Intellectual property (113)
Interviews (62)
IPO (5924)
IRA (33)
Job creations (2062)
Job search strategy (382)
JPM (29)
Kidney cancer (9)
Labor market (28)
Layoffs (206)
Leadership (8)
Legal (3452)
Liver cancer (22)
Longevity (8)
Lung cancer (184)
Lymphoma (123)
Machine learning (13)
Management (17)
Manufacturing (424)
MASH (67)
Medical device (1307)
Medtech (1314)
Mergers & acquisitions (9914)
Metabolic disorders (443)
Multiple sclerosis (48)
NASH (14)
Neurodegenerative disease (85)
Neuropsychiatric disorders (37)
Neuroscience (895)
Neurotech (1)
NextGen: Class of 2026 (1596)
Non-profit (602)
Now hiring (17)
Obesity (236)
Opinion (142)
Ovarian cancer (39)
Pain (113)
Pancreatic cancer (51)
Parkinson's disease (80)
Partnered (11)
Patents (221)
Patient recruitment (117)
Peanut (12)
People (29786)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase 1 (8334)
Phase 2 (13540)
Phase 3 (12220)
Pipeline (1942)
Policy (139)
Postmarket research (1402)
Preclinical (3344)
Press Release (25)
Prostate cancer (85)
Psychedelics (16)
Radiopharmaceuticals (137)
Rare diseases (361)
Real estate (2663)
Recruiting (21)
Regulatory (10982)
Reports (15)
Research institute (575)
Resumes & cover letters (59)
Rett syndrome (5)
RNA editing (6)
RSV (20)
Schizophrenia (70)
Series A (83)
Series B (54)
Service/supplier (2)
Sickle cell disease (49)
Special edition (11)
Spinal muscular atrophy (82)
Sponsored (9)
Startups (1652)
State (2)
Stomach cancer (5)
Supply chain (49)
Tariffs (69)
The Weekly (54)
Vaccines (238)
Venture capital (35)
Weight loss (143)
Women's health (28)
Worklife (4)
Date
Today (57)
Last 7 days (191)
Last 30 days (746)
Last 365 days (10487)
2026 (1044)
2025 (10755)
2024 (12532)
2023 (14279)
2022 (19583)
2021 (20096)
2020 (19065)
2019 (14914)
2018 (11730)
2017 (13910)
2016 (13142)
2015 (15482)
2014 (12427)
2013 (10598)
2012 (11397)
2011 (11927)
2010 (10892)
Location
Africa (323)
Alabama (19)
Alaska (1)
Arizona (78)
Arkansas (3)
Asia (20919)
Australia (2692)
California (3200)
Canada (1491)
China (560)
Colorado (144)
Connecticut (130)
Delaware (124)
Europe (40910)
Florida (603)
Georgia (63)
Hawaii (1)
Idaho (10)
Illinois (352)
India (45)
Indiana (241)
Iowa (2)
Japan (249)
Kansas (77)
Kentucky (20)
Louisiana (4)
Maine (2)
Maryland (426)
Massachusetts (2620)
Michigan (46)
Minnesota (165)
Mississippi (1)
Missouri (33)
Montana (8)
Nebraska (7)
Nevada (16)
New Hampshire (8)
New Jersey (1403)
New Mexico (7)
New York (907)
North Carolina (625)
North Dakota (2)
Northern California (1459)
Ohio (81)
Oklahoma (5)
Oregon (18)
Pennsylvania (722)
Puerto Rico (13)
Rhode Island (17)
South America (513)
South Carolina (10)
Southern California (1396)
Tennessee (53)
Texas (457)
United States (12767)
Utah (60)
Virginia (161)
Washington D.C. (42)
Washington State (227)
West Virginia (1)
Wisconsin (38)
Wyoming (1)
274,232 Results for "vertex pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Earnings
Vertex’s New Products Dim as Analysts Eye Kidney Portfolio
The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid pain medicine Journavx and gene therapy Casgevy.
November 4, 2025
·
5 min read
·
Tristan Manalac
Deals
Vertex, Enlaza Declare War on Autoimmune Disease in Potential $2B+ Pact
Vertex Pharmaceuticals commits $45 million upfront to leverage Enlaza Therapeutics’ War-Lock platform to create drug conjugates and T cell engagers for autoimmune diseases and gentler conditioning for sickle cell/beta thalassemia gene-editing therapy Casgevy.
September 2, 2025
·
2 min read
·
Heather McKenzie
Diabetes
Vertex’s Cell Therapy Could Be ‘Functional Cure’ for Diabetes, but Market Prospects Uncertain
While BMO Capital Markets said that zimislecel is “highly encouraging” for type 1 diabetes, questions regarding its target population and Vertex’s execution hang over the cell therapy’s commercial potential.
June 23, 2025
·
2 min read
·
Tristan Manalac
Earnings
Trial Failure of Vertex’s Next-Gen Pain Drug Mars Strong Q2 Earnings
Vertex reported healthy revenue in its second quarter earnings report, though news of VX-993’s mid-stage trial results and lack of alignment with the FDA regarding an expanded label for Journavx tempered analyst reactions, sending the stock down 13%.
August 5, 2025
·
3 min read
·
Dan Samorodnitsky
Press Releases
WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager
February 3, 2026
·
2 min read
Layoffs
After Axing Diabetes Asset, Vertex Lays Off 140 Staff
The layoffs will heavily affect Vertex’s operations in Rhode Island, where the biotech will consolidate three facilities into one.
June 11, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th
January 21, 2026
·
1 min read
Press Releases
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings - January 11, 2026
January 12, 2026
·
14 min read
Press Releases
Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12
December 23, 2025
·
1 min read
Press Releases
Vertex Reports Third Quarter 2025 Financial Results
November 3, 2025
·
20 min read
1 of 27,424
Next
